Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer
DPYD rs4294451 T-allele count and male sex were significantly associated with reduced 5-FU drug exposure. DPYD rs4294451 and male sex merit further evaluation as candidate biomarkers to inform initial dosing of infusional 5-FU.
Authors
- Kathryn Cunningham Hourdequin
- Vincent Busque (ORCID: https://orcid.org/0000-0002-7725-3984)
- Wahab Khan (ORCID: https://orcid.org/0000-0002-5694-0419)
- Sophie J. Deharvengt (ORCID: https://orcid.org/0000-0003-0766-2464)
- Gregory H. Ripple
- Konstantin H. Dragnev (ORCID: https://orcid.org/0000-0001-8277-6993)
- Manik Amin (ORCID: https://orcid.org/0000-0001-8467-6152)
- Wenyan Zhao (ORCID: https://orcid.org/0000-0002-2222-377X)
- Dylan B. Ness (ORCID: https://orcid.org/0000-0003-2941-5050)
- Gabriel A. Brooks (ORCID: https://orcid.org/0000-0003-3984-9995)
- Lionel D. Lewis (ORCID: https://orcid.org/0000-0003-1164-5157)
- Tor D. Tosteson (ORCID: https://orcid.org/0000-0001-9302-4762)
- Sierra Lord-Halvorson
Institutions
- Dartmouth–Hitchcock Medical Center (US)
- University of Chicago (US)
- Dartmouth Psychiatric Research Center (US)
- Dartmouth Cancer Center
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1007/s00280-025-04851-z
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- GlaxoSmithKline
- National Institutes of Health
- Genentech
- National Cancer Institute
- Daiichi Sankyo Europe